Free Trial
NASDAQ:FTRE

Fortrea (FTRE) Stock Price, News & Analysis

$19.26 +0.76 (+4.11%)
(As of 12/20/2024 05:16 PM ET)

About Fortrea Stock (NASDAQ:FTRE)

Key Stats

Today's Range
$18.35
$19.53
50-Day Range
$16.82
$23.73
52-Week Range
$16.53
$41.02
Volume
2.65 million shs
Average Volume
1.29 million shs
Market Capitalization
$1.73 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$23.30
Consensus Rating
Reduce

Company Overview

Fortrea Holdings Inc., a contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide. The company operates through two segments: Clinical Services and Enabling Services. The Clinical Services segment provides across the clinical pharmacology and clinical development spectrum. The Enabling Services segment provides patient access and clinical trial technology solutions to customers that streamline complex randomization and optimize the trial drug supply process. The company offers delivery models that include full service, functional service provider, and hybrid service structures. It also offers phase I-IV clinical trial management, differentiated technology enabled trial solutions, and post approval services, as well as consulting services. The company serves pharmaceutical, biotechnology, and medical device organizations. Fortrea Holdings Inc. was incorporated in 2023 and is headquartered in Durham, North Carolina.

Fortrea Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
52nd Percentile Overall Score

FTRE MarketRank™: 

Fortrea scored higher than 52% of companies evaluated by MarketBeat, and ranked 337th out of 947 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Fortrea has received a consensus rating of Reduce. The company's average rating score is 1.92, and is based on no buy ratings, 11 hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    Fortrea has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Fortrea's stock forecast and price target.
  • Earnings Growth

    Earnings for Fortrea are expected to grow by 147.37% in the coming year, from $0.57 to $1.41 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Fortrea is -5.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Fortrea is -5.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Growth Ratio

    Fortrea has a PEG Ratio of 2.94. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Fortrea has a P/B Ratio of 0.98. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    5.89% of the float of Fortrea has been sold short.
  • Short Interest Ratio / Days to Cover

    Fortrea has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Fortrea has recently decreased by 4.54%, indicating that investor sentiment is improving.
  • Dividend Yield

    Fortrea does not currently pay a dividend.

  • Dividend Growth

    Fortrea does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    5.89% of the float of Fortrea has been sold short.
  • Short Interest Ratio / Days to Cover

    Fortrea has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Fortrea has recently decreased by 4.54%, indicating that investor sentiment is improving.
  • News Sentiment

    Fortrea has a news sentiment score of 0.48. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Fortrea this week, compared to 5 articles on an average week.
  • Search Interest

    8 people have searched for FTRE on MarketBeat in the last 30 days. This is an increase of 700% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added Fortrea to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Fortrea insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 0.12% of the stock of Fortrea is held by insiders.

  • Read more about Fortrea's insider trading history.
Receive FTRE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Fortrea and its competitors with MarketBeat's FREE daily newsletter.

FTRE Stock News Headlines

Most People Are Dead Wrong.
Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines about artificial intelligence. Everyone's talking about AI right now. But see, I've been talking about it for years.
Baird Downgrades Fortrea Holdings (FTRE)
Fortrea: Some Green Shoots After A Dismal Period
See More Headlines

FTRE Stock Analysis - Frequently Asked Questions

Fortrea's stock was trading at $34.90 on January 1st, 2024. Since then, FTRE shares have decreased by 44.8% and is now trading at $19.26.
View the best growth stocks for 2024 here
.

Fortrea Holdings Inc. (NASDAQ:FTRE) issued its quarterly earnings results on Friday, November, 8th. The company reported $0.23 EPS for the quarter, missing the consensus estimate of $0.25 by $0.02. The company's revenue for the quarter was down 5.4% compared to the same quarter last year.

Fortrea's top institutional shareholders include Starboard Value LP (9.36%), Sessa Capital IM L.P. (7.71%), Pacer Advisors Inc. (6.84%) and FMR LLC (5.38%). Insiders that own company stock include Thomas Pike and Peter M Neupert.
View institutional ownership trends
.

Shares of FTRE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Fortrea investors own include AUO (AUOTY), Waste Connections (WCN), American Water Works (AWK), The RMR Group (RMR), DiamondRock Hospitality (DRH), iShares Micro-Cap ETF (IWC) and Triple Flag Precious Metals (TFPM).

Company Calendar

Last Earnings
11/08/2024
Today
12/20/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Medical laboratories
Sub-Industry
Healthcare
Current Symbol
NASDAQ:FTRE
Fax
N/A
Employees
18,000
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$23.30
High Stock Price Target
$27.00
Low Stock Price Target
$20.00
Potential Upside/Downside
+21.0%
Consensus Rating
Reduce
Rating Score (0-4)
1.92
Research Coverage
12 Analysts

Profitability

Net Income
$-3,400,000.00
Pretax Margin
-8.04%

Debt

Sales & Book Value

Annual Sales
$2.98 billion
Cash Flow
$2.46 per share
Book Value
$19.58 per share

Miscellaneous

Free Float
89,592,000
Market Cap
$1.73 billion
Optionable
Optionable
Beta
1.16
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

This page (NASDAQ:FTRE) was last updated on 12/21/2024 by MarketBeat.com Staff
From Our Partners